Alseres Pharmaceuticals, Inc. (ALSE)
USD 0.01
(100.0%)
USD 0.01
(100.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2013 | 7.7 Million USD | 20.53% |
| 2012 | 6.39 Million USD | -76.83% |
| 2011 | 27.59 Million USD | -18.02% |
| 2010 | 33.65 Million USD | -4.76% |
| 2009 | 35.33 Million USD | 5.25% |
| 2008 | 33.57 Million USD | 64.57% |
| 2007 | 20.4 Million USD | 214.29% |
| 2006 | 6.49 Million USD | 2234.05% |
| 2005 | -304.17 Thousand USD | -98.85% |
| 2004 | -152.97 Thousand USD | 93.28% |
| 2003 | -2.27 Million USD | -174.05% |
| 2002 | 3.07 Million USD | 1170.47% |
| 2001 | -287.3 Thousand USD | 29.47% |
| 2000 | -407.32 Thousand USD | -109.47% |
| 1999 | 4.3 Million USD | 4400.0% |
| 1998 | -100 Thousand USD | 94.12% |
| 1997 | -1.7 Million USD | 80.0% |
| 1996 | -8.5 Million USD | -8600.0% |
| 1995 | 100 Thousand USD | 104.17% |
| 1994 | -2.4 Million USD | 36.84% |
| 1993 | -3.8 Million USD | -72.73% |
| 1992 | -2.2 Million USD | 33.33% |
| 1991 | -3.3 Million USD | 65.26% |
| 1990 | -9.5 Million USD | -102.13% |
| 1989 | -4.7 Million USD | -104.35% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2014 Q2 | 8.36 Million USD | 4.16% |
| 2014 Q1 | 8.03 Million USD | 4.27% |
| 2013 FY | 7.7 Million USD | 20.53% |
| 2013 Q2 | 6.43 Million USD | 1.82% |
| 2013 Q4 | 7.7 Million USD | 15.74% |
| 2013 Q3 | 6.65 Million USD | 3.51% |
| 2013 Q1 | 6.31 Million USD | -1.19% |
| 2012 Q2 | 27.94 Million USD | 1.24% |
| 2012 FY | 6.39 Million USD | -76.83% |
| 2012 Q1 | 27.6 Million USD | 0.05% |
| 2012 Q3 | 12.21 Million USD | -56.3% |
| 2012 Q4 | 6.39 Million USD | -47.65% |
| 2011 Q1 | 34.32 Million USD | 1.99% |
| 2011 Q4 | 27.59 Million USD | -22.31% |
| 2011 Q3 | 35.51 Million USD | 1.39% |
| 2011 FY | 27.59 Million USD | -18.02% |
| 2011 Q2 | 35.02 Million USD | 2.04% |
| 2010 Q1 | 36.44 Million USD | 3.14% |
| 2010 Q3 | 32.94 Million USD | -11.82% |
| 2010 Q4 | 33.65 Million USD | 2.17% |
| 2010 FY | 33.65 Million USD | -4.76% |
| 2010 Q2 | 37.36 Million USD | 2.5% |
| 2009 Q3 | 34.93 Million USD | -0.05% |
| 2009 Q2 | 34.95 Million USD | 1.9% |
| 2009 Q4 | 35.33 Million USD | 1.15% |
| 2009 Q1 | 34.3 Million USD | 2.17% |
| 2009 FY | 35.33 Million USD | 5.25% |
| 2008 FY | 33.57 Million USD | 64.57% |
| 2008 Q4 | 33.57 Million USD | 5.07% |
| 2008 Q3 | 31.95 Million USD | 14.77% |
| 2008 Q2 | 27.84 Million USD | 20.31% |
| 2008 Q1 | 23.14 Million USD | 13.44% |
| 2007 Q2 | 12.17 Million USD | -30.3% |
| 2007 FY | 20.4 Million USD | 214.29% |
| 2007 Q4 | 20.4 Million USD | 17.95% |
| 2007 Q3 | 17.29 Million USD | 42.02% |
| 2007 Q1 | 17.47 Million USD | 169.19% |
| 2006 FY | 6.49 Million USD | 2234.05% |
| 2006 Q4 | 6.49 Million USD | 920.11% |
| 2006 Q2 | -1.63 Million USD | -956.01% |
| 2006 Q1 | 191.18 Thousand USD | 162.85% |
| 2006 Q3 | 636.33 Thousand USD | 138.88% |
| 2005 FY | -304.17 Thousand USD | -98.85% |
| 2005 Q1 | -3.76 Million USD | -2360.92% |
| 2005 Q2 | -1.21 Million USD | 67.82% |
| 2005 Q3 | -2.97 Million USD | -145.26% |
| 2005 Q4 | -304.17 Thousand USD | 89.76% |
| 2004 Q4 | -152.97 Thousand USD | -103.76% |
| 2004 FY | -152.97 Thousand USD | 93.28% |
| 2004 Q1 | 2.51 Million USD | 210.27% |
| 2004 Q2 | 2.9 Million USD | 15.78% |
| 2004 Q3 | 4.06 Million USD | 39.91% |
| 2003 FY | -2.27 Million USD | -174.05% |
| 2003 Q2 | 2.55 Million USD | 145.61% |
| 2003 Q3 | 2.34 Million USD | -8.46% |
| 2003 Q4 | -2.27 Million USD | -197.29% |
| 2003 Q1 | -5.6 Million USD | -282.28% |
| 2002 Q1 | -2.86 Million USD | -896.08% |
| 2002 Q3 | -1.66 Million USD | -277.86% |
| 2002 FY | 3.07 Million USD | 1170.47% |
| 2002 Q4 | 3.07 Million USD | 284.46% |
| 2002 Q2 | -441.24 Thousand USD | 84.58% |
| 2001 Q2 | -3.53 Million USD | -27.14% |
| 2001 Q1 | -2.78 Million USD | -583.54% |
| 2001 Q4 | -287.3 Thousand USD | 87.97% |
| 2001 FY | -287.3 Thousand USD | 29.47% |
| 2001 Q3 | -2.38 Million USD | 32.52% |
| 2000 Q3 | -1.52 Million USD | 67.01% |
| 2000 Q2 | -4.62 Million USD | -714.98% |
| 2000 Q1 | -567.93 Thousand USD | -113.21% |
| 2000 FY | -407.32 Thousand USD | -109.47% |
| 2000 Q4 | -407.32 Thousand USD | 73.32% |
| 1999 FY | 4.3 Million USD | 4400.0% |
| 1999 Q4 | 4.3 Million USD | 216.22% |
| 1999 Q3 | -3.7 Million USD | -1133.33% |
| 1999 Q2 | -300 Thousand USD | 94.64% |
| 1999 Q1 | -5.6 Million USD | -5500.0% |
| 1998 FY | -100 Thousand USD | 94.12% |
| 1998 Q1 | -1.5 Million USD | 11.76% |
| 1998 Q3 | -2.8 Million USD | -366.67% |
| 1998 Q4 | -100 Thousand USD | 96.43% |
| 1998 Q2 | -600 Thousand USD | 60.0% |
| 1997 Q4 | -1.7 Million USD | 59.52% |
| 1997 FY | -1.7 Million USD | 80.0% |
| 1997 Q3 | -4.2 Million USD | 10.64% |
| 1997 Q2 | -4.7 Million USD | 28.79% |
| 1997 Q1 | -6.6 Million USD | 22.35% |
| 1996 Q4 | -8.5 Million USD | 23.42% |
| 1996 Q3 | -11.1 Million USD | 54.88% |
| 1996 Q2 | -24.6 Million USD | -16.04% |
| 1996 FY | -8.5 Million USD | -8600.0% |
| 1996 Q1 | -21.2 Million USD | -21300.0% |
| 1995 Q4 | 100 Thousand USD | 0.0% |
| 1995 FY | 100 Thousand USD | 104.17% |
| 1995 Q1 | -2.3 Million USD | 4.17% |
| 1995 Q2 | -400 Thousand USD | 82.61% |
| 1995 Q3 | - USD | 100.0% |
| 1994 FY | -2.4 Million USD | 36.84% |
| 1994 Q4 | -2.4 Million USD | 31.43% |
| 1994 Q3 | -3.5 Million USD | -9.38% |
| 1994 Q2 | -3.2 Million USD | 5.88% |
| 1994 Q1 | -3.4 Million USD | 10.53% |
| 1993 Q2 | -13.9 Million USD | -363.33% |
| 1993 FY | -3.8 Million USD | -72.73% |
| 1993 Q1 | -3 Million USD | -36.36% |
| 1993 Q3 | -6.8 Million USD | 51.08% |
| 1993 Q4 | -3.8 Million USD | 44.12% |
| 1992 Q1 | -2.5 Million USD | 24.24% |
| 1992 Q3 | -1.3 Million USD | 27.78% |
| 1992 Q4 | -2.2 Million USD | -69.23% |
| 1992 FY | -2.2 Million USD | 33.33% |
| 1992 Q2 | -1.8 Million USD | 28.0% |
| 1991 Q1 | -7.8 Million USD | 17.89% |
| 1991 Q4 | -3.3 Million USD | -50.0% |
| 1991 FY | -3.3 Million USD | 65.26% |
| 1991 Q3 | -2.2 Million USD | 0.0% |
| 1990 Q4 | -9.5 Million USD | 0.0% |
| 1990 FY | -9.5 Million USD | -102.13% |
| 1989 FY | -4.7 Million USD | -104.35% |
| 1989 Q4 | -4.7 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | 588344.427% |
| Arch Therapeutics, Inc. | 5.64 Million USD | -36.429% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 81.992% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 3187.093% |
| Rebus Holdings, Inc. | 305 Thousand USD | -2426.558% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 222.23% |
| Qrons Inc. | 351.42 Thousand USD | -2092.775% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -1138.182% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 82.258% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 37859.712% |
| Skye Bioscience, Inc. | -5.72 Million USD | 234.688% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 51.113% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | -87.129% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -1817.636% |
| SQZ Biotechnologies Company | -36.23 Million USD | 121.265% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | -243.675% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -731.117% |
| Mesoblast Limited | 55.85 Million USD | 86.204% |
| Marizyme, Inc. | 18.56 Million USD | 58.501% |
| Genus plc | 190.6 Million USD | 95.957% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | -244.659% |
| Pharming Group N.V. | 109.8 Million USD | 92.982% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -795.796% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -534.82% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -1033.236% |
| ContraFect Corporation | -6.02 Million USD | 227.879% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -5623.455% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -566.939% |
| IMV Inc. | 7.67 Million USD | -0.463% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | -40.061% |
| MultiCell Technologies, Inc. | 90.04 USD | -8558320.702% |
| ONE Bio Corp. | 9.04 Million USD | 14.757% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 1149.896% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 40.476% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | -463.316% |
| Q BioMed Inc. | 4.06 Million USD | -89.803% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 74.779% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -664.7% |
| Biomind Labs Inc. | 711.4 Thousand USD | -983.213% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 87.272% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | -285.417% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 39.828% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -2042.282% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -5412.004% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -38687.95% |
| Curative Biotechnology, Inc. | 2.2 Million USD | -249.958% |
| GB Sciences, Inc. | 1.74 Million USD | -341.019% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 4292.875% |
| HST Global, Inc. | 96.79 Thousand USD | -7861.322% |
| CSL Limited | 10.52 Billion USD | 99.927% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -3636.841% |
| Halberd Corporation | 144.72 Thousand USD | -5224.73% |
| Enzolytics Inc. | 981.65 Thousand USD | -685.0% |
| Agentix Corp. | 37.63 Thousand USD | -20377.803% |
| Resverlogix Corp. | 6.45 Million USD | -19.454% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 1244.871% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 100.38% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 116.392% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -8.981% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -184.5% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 187.173% |
| AVAX Technologies, Inc. | -5.9 Million USD | 230.539% |
| Zenith Capital Corp. | 10.06 Thousand USD | -76469.972% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.726% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -3744.696% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | -222.963% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -4584.243% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 42167.922% |
| Kadimastem Ltd | -253.1 Thousand USD | 3144.623% |
| Helix BioMedix, Inc. | -2.57 Million USD | 399.841% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 61.994% |
| BioStem Technologies, Inc. | 4.47 Million USD | -72.316% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -3728.993% |
| LadRx Corporation | -2.03 Million USD | 478.4% |
| Cell Source, Inc. | 9.23 Million USD | 16.529% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -1113.225% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -1113.225% |
| NovAccess Global Inc. | 2.17 Million USD | -253.735% |
| Affymax, Inc. | -5.59 Million USD | 237.681% |
| Itoco Inc. | 228.3 Thousand USD | -3275.31% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -5566.636% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | -55.457% |
| Mobile Lads Corp. | 484.23 Thousand USD | -1491.386% |
| CytoDyn Inc. | 20.26 Million USD | 61.968% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 1191135.858% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 83243.281% |
| SYBLEU INC | 473.71 Thousand USD | -1526.72% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | -72.896% |
| International Stem Cell Corporation | 2.59 Million USD | -197.529% |
| Bioxytran, Inc. | 1.89 Million USD | -305.811% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -12246.79% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -253.34% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | -124.403% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 9.903% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -897.403% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 716.48% |
| Neutra Corp. | 52.18 Thousand USD | -14666.133% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 409.602% |
| PureTech Health plc | -167.19 Million USD | 104.609% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 3246.488% |
| IXICO plc | -4.44 Million USD | 273.379% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 41.705% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 85.951% |
| CSL Limited | 10.52 Billion USD | 99.927% |
| Cellectis S.A. | -43.81 Million USD | 117.586% |